IN VITRO STUDIES OF RADIUM-223 AND ACTINIUM-225 LABELLED Α-ZIRCONIUM PHOSPHATE AS POTENTIAL CARRIER FOR ALPHA TARGETED THERAPY

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68407700%3A21340%2F22%3A00362320" target="_blank" >RIV/68407700:21340/22:00362320 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

IN VITRO STUDIES OF RADIUM-223 AND ACTINIUM-225 LABELLED Α-ZIRCONIUM PHOSPHATE AS POTENTIAL CARRIER FOR ALPHA TARGETED THERAPY

Popis výsledku v původním jazyce

Targeted alpha particle therapy (TAT), which uses radionuclides emitting alpha particles is one of the promising possibilities for the treatment of a broad range of malignancies. A short range of alpha particles in soft tissues (approx. 50-100 μm) and high linear energy transfer (LET) allows to destroy tumor cells effectively. Precise targeting by appropriate carrier should ensure efficient and accurate destruction of target cancer tissue while keeping healthy tissues intact. Currently, there are only few such radionuclides that are suitable for use in nuclear medicine. Two widely employed radionuclides, the 223Ra and the 225Ac, are among the most potential radionuclides suitable for targeted alpha therapy. Nanoparticles can serve as suitable radionuclide carriers for TAT, particularly considering their ability to at least partially stop the progeny recoils spread and keep the daughter atoms immobilised in their structure. At the same time these nanoparticles can be surfacemodified, which may improve their targeting, stability and other biological and chemical properties2,3. Nanoparticles of α-zirconium phosphate (α-ZrP) were selected and tested as potential carriers of 223Ra and 225Ac in this study. Nanoparticles of α-ZrP were prepared by the reaction of zirconium oxychloride octahydrate aqueous solution with sodium dihydrogen phosphate solution in hydrochloric acid under reflux. The prepared particles were washed by deionised water and then redispersed in ultrapure water. The size of the particles was determined using dynamic light scattering method and the Ζ-potentials were also measured. Consequently, samples were labelled in aqueous solution with 223Ra and 225Ac. The labelling yield exceeded 98 % in most cases both for 223Ra and 225Ac. Subsequently, in vitro stability studies were carried out in four biological matrices: blood serum, blood plasma, saline and 5 % albumin solution during 48 h period. Measurements of released activities revealed that samples exhibit the highest stability in saline. Released activity of 223Ra, 225Ac and their daughter radionuclides was around 0,5 %. On the other hand, the lowest stability was shown in blood plasma for 223Ra, where released activity was above 15 % and 18 % for 211Pb and 211Bi after 48 h. In blood serum was measured highest release activity for 225Ac (close to 18 %) and its daughter radionuclides 221Fr (more than 20 %) and 213Bi (above 32 %).

Název v anglickém jazyce

IN VITRO STUDIES OF RADIUM-223 AND ACTINIUM-225 LABELLED Α-ZIRCONIUM PHOSPHATE AS POTENTIAL CARRIER FOR ALPHA TARGETED THERAPY

Popis výsledku anglicky

Targeted alpha particle therapy (TAT), which uses radionuclides emitting alpha particles is one of the promising possibilities for the treatment of a broad range of malignancies. A short range of alpha particles in soft tissues (approx. 50-100 μm) and high linear energy transfer (LET) allows to destroy tumor cells effectively. Precise targeting by appropriate carrier should ensure efficient and accurate destruction of target cancer tissue while keeping healthy tissues intact. Currently, there are only few such radionuclides that are suitable for use in nuclear medicine. Two widely employed radionuclides, the 223Ra and the 225Ac, are among the most potential radionuclides suitable for targeted alpha therapy. Nanoparticles can serve as suitable radionuclide carriers for TAT, particularly considering their ability to at least partially stop the progeny recoils spread and keep the daughter atoms immobilised in their structure. At the same time these nanoparticles can be surfacemodified, which may improve their targeting, stability and other biological and chemical properties2,3. Nanoparticles of α-zirconium phosphate (α-ZrP) were selected and tested as potential carriers of 223Ra and 225Ac in this study. Nanoparticles of α-ZrP were prepared by the reaction of zirconium oxychloride octahydrate aqueous solution with sodium dihydrogen phosphate solution in hydrochloric acid under reflux. The prepared particles were washed by deionised water and then redispersed in ultrapure water. The size of the particles was determined using dynamic light scattering method and the Ζ-potentials were also measured. Consequently, samples were labelled in aqueous solution with 223Ra and 225Ac. The labelling yield exceeded 98 % in most cases both for 223Ra and 225Ac. Subsequently, in vitro stability studies were carried out in four biological matrices: blood serum, blood plasma, saline and 5 % albumin solution during 48 h period. Measurements of released activities revealed that samples exhibit the highest stability in saline. Released activity of 223Ra, 225Ac and their daughter radionuclides was around 0,5 %. On the other hand, the lowest stability was shown in blood plasma for 223Ra, where released activity was above 15 % and 18 % for 211Pb and 211Bi after 48 h. In blood serum was measured highest release activity for 225Ac (close to 18 %) and its daughter radionuclides 221Fr (more than 20 %) and 213Bi (above 32 %).

Druh

O - Ostatní výsledky

CEP obor

—

OECD FORD obor

10402 - Inorganic and nuclear chemistry

Projekt

<a href="/cs/project/TJ04000129" target="_blank" >TJ04000129: Separace radionuklidů pro cílenou alfa částicovou terapii</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů